MDCLF Stock Chart & Stats
$34.39
--
Market closed
$34.39
--
Day’s Range― - ―
52-Week Range$6.97 - $34.39
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$1.06B
Enterprise Value$790.84
Total Cash (Recent Filing)$53.50M
Total Debt (Recent Filing)$58.27M
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Dec 08, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding35,912,260
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)264.15
Price to Sales (P/S)33.34
P/FCF Ratio-32.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$40.38Price Target Upside17.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$54.67M
Bulls Say, Bears Say
Bulls Say
Proprietary Long-acting Delivery PlatformMedinCell's BEPO subcutaneous platform has >4,000 clinical injections with no PDSS events, a durable safety and technical differentiator. That clinical safety record lowers regulatory and commercial adoption barriers, supporting long-term partner confidence, licensing and recurring royalty potential.
Growing Royalty-driven Revenue MixA rising share of recurring royalties (38% vs 22%) signals structural shift from one-off milestones toward predictable income. As UZEDY sales scale and olanzapine LAI potentially starts royalties, a steadier royalty base should improve revenue durability and reduce cash reliance on lump-sum events.
Improved Liquidity And Lower LeverageZero reported debt and ~€80.8m cash provide multi-quarter runway to fund R&D and business development. Reduced leverage materially lowers near-term bankruptcy risk and gives management flexibility to invest in platform scale-up and partner-enabled programs without immediate financing events.
Bears Say
Sizable Cash Burn And Widening LossesThe company reverted to significant cash burn and a materially wider net loss in 2026, reflecting higher OpEx for R&D and BD. Persistent negative free cash flow increases funding sensitivity: absent faster royalty ramps or milestones, the firm may need financing that dilutes shareholders or alters strategic pacing.
Revenue Volatility From Milestone TimingDependence on lump-sum milestones drives year-to-year revenue lumpiness. Without consistent milestone receipts the top line swings, complicating cash flow forecasting and investment planning. Durable financial planning requires more predictable, royalty-based income to offset milestone variability.
Partner And Regulatory Execution RiskMedinCell's strategy hinges on partner commercial execution and regulatory decisions. Teva's rollouts and partner program timelines materially affect royalties and milestones. Regulatory pathway changes and partner-driven timing raise structural program risk and could delay or reduce expected recurring revenues.
MedinCell SA News
MDCLF FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was $6.97 and its highest was $34.39 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is $1.06B.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Dec 08, 2026 which is in 135 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Jun 16, 2026. The company reported -$0.514 earnings per share for the quarter, missing the consensus estimate of -$0.16 by -$0.354.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is -0.27.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 35,912,260 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -$0.514 in its last earnings report, missing expectations of -$0.16. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in MDCLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedinCell SA
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
MDCLF Stock 12 Month Forecast
Average Price Target
$40.38
▲(17.43% Upside)
Ownership Overview
―
Insiders
2.79% Mutual Funds
― Other Institutional Investors
95.68% Public Companies and
Individual Investors